TCV Trust & Wealth Management Inc. Has $11.99 Million Holdings in Zoetis Inc. $ZTS

Key Points

• TCV Trust & Wealth Management Inc. reduced its stake in Zoetis Inc. by 2.4%, selling 1,854 shares during the 2nd quarter, leaving them with 76,893 shares valued at approximately $11.99 million.
• Analysts have mixed views on Zoetis, with ratings ranging from "buy" to "hold" and price targets varying from $155.00 to $215.00, indicating a consensus target price of $200.88.
• Zoetis reported earnings of $1.76 per share for the latest quarter, surpassing expectations and showing a year-over-year revenue increase of 4.2% to $2.46 billion.

TCV Trust & Wealth Management Inc. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 76,893 shares of the company's stock after selling 1,854 shares during the period. TCV Trust & Wealth Management Inc.'s holdings in Zoetis were worth $11,991,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the company. Lindbrook Capital LLC grew its stake in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after purchasing an additional 65 shares during the period. Secure Asset Management LLC raised its stake in Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock valued at $382,000 after buying an additional 68 shares during the period. Quotient Wealth Partners LLC increased its stake in Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after acquiring an additional 72 shares during the period. Broadway Wealth Solutions Inc. raised its holdings in shares of Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after buying an additional 73 shares in the last quarter. Finally, Menard Financial Group LLC increased its holdings in Zoetis by 3.8% in the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after purchasing an additional 75 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.9%

Zoetis stock traded down $1.28 during mid-day trading on Friday, reaching $145.82. 4,455,824 shares of the company's stock were exchanged, compared to its average volume of 2,273,605. The company has a market cap of $64.63 billion, a P/E ratio of 25.10, a P/E/G ratio of 2.34 and a beta of 0.89. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $197.51. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a fifty day moving average of $151.25 and a 200-day moving average of $156.52.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on ZTS shares. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Argus restated a "buy" rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Zoetis has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.